Acute myocardial infarction (AMI) causes cardiac tissue damage and creates a transient leaky vasculature, which is an attractive target for intravascular therapeutics. Nanomaterials have the potential to deliver therapeutics to the injured heart, yet the influence of particle size, shape, and surface decoration on infarct localization has not been systematically examined. Here, we evaluated a self‐assembling peptide platform that can be tuned to form high aspect ratio nanofibers or globular nanoparticles by modifying the β sheet forming domain. This platform has tunable nanofiber length distribution via sonication and aging as well as surface decoration via targeting peptides. In a rat model of AMI, the incorporation of a type IV collagen targeting peptides significantly increased localization of the nanofibers to the injured leaky vasculature while globular peptides diffuse through and targeted the infarcted myocardium. These results demonstrate that this modular peptide nanomaterial can be tuned via geometry and surface moieties to either target to the compromised vasculature components or infiltrate the infarct. This study establishes size, shape, and surface decoration as critical features for effective intravascular nanomaterial delivery after AMI.

Receptor‐targeting ligands can improve the specificity and cellular uptake of drugs and gene delivery systems. However, there is currently a lack of rapid, high‐throughput assays to identify ligands that efficiently induce endocytosis. To address this gap, we developed a flow cytometric assay that selectively quantifies internalized fluorescence, directly converting endosomal uptake into an easily measurable signal across entire cell populations and avoiding the ambiguity and labor intensity of microscopy‐based methods. Using this platform, we identified ligands that induce cellular uptake and applied them to the TFAMoplex, a modular, protein‐based nonviral gene delivery system recently developed in our group. Coupling of heparin‐binding epidermal growth factor, identified as an efficient internalizing ligand with the endocytosis assay, enhanced TFAMoplex uptake and transfection efficacy. These results support a generalizable strategy to rapidly screen uptake ligands, enabling the rational design of improved nonviral gene delivery systems.

Ultrasound Contrast Agents The cover illustration depicts an engineered nanobubble ultrasound contrast agent designed for theranostic applications in drug delivery, gene therapy, and immunomodulation. The nanobubble features a multifunctional hybrid shell integrating lipid layers (yellow), polymeric coatings (green), and nanoparticle-based components (red), representing versatile structural architectures that enhance stability, responsiveness, and targeting capabilities. Inside the nanobubble core, various therapeutic cargos (including drugs, genes, and immune agents) are depicted, symbolizing the broad use of microbubbles and nanobubbles that can be encapsulated for controlled, ultrasound-triggered release. Overall, the image visually summarizes the central theme of the review: how rationally engineered ultrasound contrast agents can serve as theranostic platforms uniting imaging and targeted therapy across drug delivery, gene therapy, and immunomodulation. More details can be found in the Research Article by Sara Minaeian and co-workers (DOI: 10.1002/anbr.202500176).

Acne vulgaris is a prevalent chronic inflammatory skin disease, for which topical pharmacotherapy remains challenging due to the skin barrier and complex pathological mechanisms. In recent years, micro/nanocarrier‐based dermal delivery systems have emerged as novel strategies to overcome these barriers. These carriers can significantly enhance local drug bioavailability, targeting precision, and therapeutic duration. Furthermore, by integrating functionally complementary carriers, synergistic effects can be achieved across spatial, temporal, and biological dimensions, offering a systematic intervention for this multifactorial condition. However, the clinical translation of such technologies is still hindered by several challenges, including scalable manufacturing processes, long‐term safety evaluation, reliable preclinical models, and harmonized regulatory standards. Looking forward, the convergence of multiomics diagnostics and digital manufacturing is expected to advance intelligent closed‐loop systems capable of real‐time sensing and adaptive regulation, thereby enabling truly personalized and precise treatment. This progress will shift acne management from symptomatic control toward modulation of the underlying pathology.

Enzymes, as biological catalysts, are widely used for their excellent selectivity and sensitivity, playing a crucial role in biosensors, offering significant potential for monitoring food products and health conditions. However, enzyme activity can be compromised by environmental factors like high humidity, pH, and temperature variations. This study explores the feasibility of improving the stability of the unstable enzyme lipoxygenase (LOX) through immobilization using silk, a naturally occurring fibrous protein. A linoleic acid biosensor is designed by combining silk‐entrapped LOX with poly(3,4‐ethyloxy thiophene):poly(styrene sulfonate) (PEDOT:PSS) and horseradish peroxidase (HRP). The findings demonstrate that immobilizing LOX with different molecular weight silks extends the shelf‐life of the freeze‐dried PEDOT:PSS/HRP/LOX more than tenfold, from less than 1 day to 10 days. The results of the characterization tests (e.g., Fourier transform infrared spectroscopy, rheology) highlighted the interdependency between silk properties, such as its molecular weight, the silk conformation, and the pore shape and size, and enzyme stability. Low molecular weight silk resulted in the best performance, enabling storage at room temperature. It can therefore be concluded that immobilization with silk is an efficient method to enhance the shelf‐life of enzyme‐based biosensors, for diagnostic and other applications.

Mechanoadaptive Responses In this cover image, the newly found mechanoadaptive response of neutrophils adhesion and the membrane tether coalescence MI-SIM super-resolution images under abrupt flow acceleration are emphasized and represented. More details can be found in the Research Article by Lining Arnold Ju and co-workers (DOI: 10.1002/anbr.202500113).

Mitochondrial dysfunction and oxidative stress are key contributors to impaired vascular healing following stent implantation. Although drug‐eluting stents reduce restenosis, they do not promote tissue regeneration or correct cellular metabolic deficits. A redox‐responsive mitochondrial delivery system is developed for localized therapeutic release from vascular stent surfaces. Intact mitochondria are immobilized onto Nitinol substrates through a stepwise surface modification strategy incorporating a reactive oxygen species (ROS)‐cleavable linker. Upon exposure to elevated ROS levels, mitochondria are released in a dose‐dependent manner and internalized by human endothelial cells and vascular smooth muscle cells. Transmission electron microscopy confirms the integrity of isolated mitochondria, and X‐ray photoelectron spectroscopy and secondary ion mass spectrometry validate successful surface functionalization and grafting. The modified surfaces demonstrate high biocompatibility, with minimal cytotoxicity and reduced platelet adhesion. Released mitochondria restore mitochondrial membrane potential, oxygen consumption rate and enhance cell viability under oxidative stress. Ex vivo assessment in rat aortic tissue provides visual confirmation of mitochondrial uptake in a physiologically relevant context. This platform establishes a stimulus‐responsive, organelle‐based therapeutic strategy that targets mitochondrial dysfunction at the biomaterial–tissue interface and offers potential to enhance vascular regeneration in oxidative microenvironments following endovascular interventions.

Anticancer cell therapies have remarkable clinical potential yet fail to reach the clinic due to poor delivery. 3D bioprinting (3DBP) can be leveraged for generating cell therapy delivery devices, where the biomaterial system acts as a protective matrix to stabilize cells after implantation. Continuous liquid interface production (CLIP), an additive manufacturing technology, has several unique features that make it a suitable platform for 3DBP of cell-laden scaffolds. However, the feasibility CLIP bioprinting and efficacy of CLIP-bioprinted cell/matrix therapies have not yet been explored. In this work, we demonstrate the utility of CLIP for cell therapy 3DBP with a simple gelatin methacrylate-based resin and anticancer drug-secreting fibroblasts as a model therapy against recurrent glioblastoma. We demonstrate that CLIP enables rapid, consistent production of cell-laden scaffolds, and cells maintain their viability and tumor-killing efficacy in vitro post-printing. Importantly, we proved that bioprinted cells survive longer in vivo than directly injected cells, and that this effect may correspond to better survival outcomes in a mouse model of glioblastoma resection. This study is the first to utilize CLIP for 3DBP of composite devices containing anticancer cell therapies, providing a crucial foundation for developing highly refined cell therapy delivery devices in the future.

In this study, the potential of maghemite (γ‐Fe 2 O 3 ) nanoparticles (MNPs) functionalized with doxorubicin (DOX) is explored for chemo‐magneto‐photothermal therapy in cancer treatment. MNPs are functionalized through electrostatic interactions or disulfide bonds, achieving high drug‐loading efficiencies. The trimodal approach combines magnetic hyperthermia (MHT), photothermal therapy (PTT) and local chemotherapy, utilizing low and clinically relevant doses. Thermal treatments induced controlled temperature increases, triggering pH‐sensitive DOX release in the acidic environments typical of tumors. Efficient uptake of DOX‐loaded MNPs is observed, and their structural integrity is confirmed using advanced synchrotron spectroscopic techniques. Cytotoxicity assays show that MHT and PTT together enhanced therapeutic efficacy compared to free DOX, while minimizing toxicity to healthy cells. This study demonstrates that combining thermal therapies with controlled drug release provides a promising strategy for improving cancer treatment outcomes. The findings highlight the potential clinical application of multifunctional nanoparticle systems for targeted, low‐toxicity cancer therapies, advancing the path toward more effective and accessible treatments.